An observational study in Heart Failure and Preserved Ejection Fraction, sponsored by Boehringer Ingelheim. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Failure by Boehringer Ingelheim — 4 open to participants now, 4 under way, 2 of them phase 3. Heart Failure · Boehringer Ingelheim.
Among the 14 studies in Heart Failure by Boehringer Ingelheim, this one is one of 2 that started in 2028, is one of 6 observational ones, and was the 13th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →4 of the 14 studies in Heart Failure by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Belgium and 26 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 27 more countries
Ages 18+
Boehringer Ingelheim · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2028.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 200 across 1,985 observational studies indexed under Heart Failure.
Median enrollment 2,130 across the 8 interventional studies, 3,216 across the 6 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Heart Failure by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
Chines patients with a heart failure and preserved ejection fraction (HFpEF) diagnosis who initiate Jardiance® after 1st of March 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
-Patients treated with any other sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the index date or during the look-back period
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of the composite outcome of HHF (the first HHF after the index date) or CV death
HHF=Hospitalization for Heart Failure CV=cardiovascular
Time frame: up to 2.5 years
Incidence of CV death
Time frame: up to 2.5 years
Incidence of the HHF (the first HHF after the index date)
Time frame: up to 2.5 years
Occurrence of death from any cause
Time frame: up to 2.5 years
No study locations are listed for this record.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Start is estimated for Jan 2028; primary completion for Dec 2028, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.